On July 20, the US Food and Drug Administration approved GlaxoSmithKline’s Krintafel (tafenoquine), a single-dose treatment to prevent relapses of Plasmodium vivax, a malaria parasite that causes more than eight million infections annually. “This drug could be transformative,” says David Reddy, executive
director of Medicines for Malaria Venture, GlaxoSmithKline’s partner in the development of Krintafel. On August 9, the FDA also gave the go-ahead to 60 Degrees Pharmaceuticals for a six-month dosing regimen of tafenoquine tablets, commercialized as Arakoda, to prevent malaria in adults, including travelers and residents of disease-endemic countries…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 9 SEPTEMBER 2018 785